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Abstract
Introduction: A recent metabolomic screen of sera from patients with Systemic Lupus Erythematosus (SLE) found
reduction of antioxidants and substrates for energy generation. These metabolic alterations may underlie one of the
most common features of SLE - fatigue. The metabolomic studies also noted reduced omega-3 fatty acids, which
are powerful anti- oxidants. This deficiency may be causally related to oxidative stress, inflammation, disease activity,
and fatigue in SLE. Supplementation of omega-3 fatty acids using fish oil in SLE has been shown to reduce
oxidative stress in other studies. The objective of this study is to evaluate the effect of fish oil supplementation on
clinical measures of fatigue, quality of life, and disease activity as part of a randomized clinical trial.
Methods: Fifty SLE patients recruited in outpatient clinics were randomized 1:1 to fish oil supplementation or olive oil
placebo, and blinded to their treatment group. At baseline and after 6 months of treatment, RAND Short Form-36
(RAND SF-36), Fatigue Severity Scale (FSS), SLE Disease Activity Index (SLEDAI), and Physician Global Assessment (PGA)
were completed; serum was also collected for soluble mediator analysis.
Results: Thirty-two patients completed the study. PGA improved significantly in the fish oil group compared with
the placebo group (p = 0.015). The RAND SF-36 Energy/fatigue and Emotional well-being scores demonstrated
improvement trends (p = 0.092 and 0.070). No clear difference was seen in FSS and SLEDAI (p = 0.350 and p = 0.417).
Erythrocyte sedimentation rate and serum IL-12 were reduced (p = 0.008 and p = 0.058); while serum IL-13 was
increased by fish oil supplementation (p = 0.033).
Conclusions: In this randomized, placebo-controlled 6-month trial, SLE patients randomized to fish oil
supplementation demonstrated improvement in their PGA, RAND SF-36, and some circulating inflammatory markers.
Trial registration: ClinicalTrials.gov Identifier: NCT02021513 (registered 13 December 2013).
Introduction
Systemic lupus erythematosus (SLE) is a complex auto-
immune disease varying widely in attributes and severity
[1, 2]. SLE patients differ from healthy individuals on mul-
tiple biological levels including immune cell function, single
nucleotide polymorphisms, modified gene expression, as
well as metabolic cycle intermediate quantity changes [3].
A comprehensive metabolomic scan revealed a reduction
in omega-3 fatty acids in SLE patients compared to
healthy controls [4]. Previous studies in SLE noted similar
reduction of eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA), the omega-3 fatty acid components of
fish oil [5, 6]. These deficiencies have prompted several
fish oil supplement clinical trials in SLE with a variety of
outcomes assessed. A recent study evaluated the effect of
fish oil on flow-mediated dilation, disease activity,
sICAM-1, sVCAM-1, IL-6, and fasting lipid panel, and re-
ported negative findings with the exception of LDL eleva-
tion in the fish oil group [7]. However, in another study,
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SLE patients given fish oil had improved flow-mediated
dilation, disease activity, and 8- isoprostanes [8]. A study of
EPA alone in six lupus nephritis patients noted significant
reduction in urinary 8-isoprostane [9]. An elegant study by
Groeger et al. details a possible mechanism for omega-3
fatty acids’ anti-oxidant and anti-inflammatory effects [10].
Disease activity improved in patients receiving fish oil as
compared to placebo, however erythrocyte sedimentation
rate (ESR) did not improve in a study evaluating fish oil
and copper in SLE patients [11]. In another study, lupus
nephritis patients treated with fish oil exhibited no signifi-
cant reduction in SLE disease activity or improvement in
renal function, but had reduction of VLDL and triglycerides
compared to the olive oil placebo group [12]. Utilizing a
unique improvement or deterioration scale, another study
noted significant improvement in SLE patients adminis-
tered fish oil compared to olive oil placebo [13]. Disease ac-
tivity, immune complexes, and proteinuria were not
reduced with 2 different doses of fish oil in lupus nephritis
patients, however arachidonic acid, leukotriene B4, VLDL,
triglycerides, and whole blood viscosity were reduced [14].
Beyond reinforcing the finding of reduced omega-3 fatty
acids in SLE patients, our previously reported metabolo-
mics study also uncovered reduction of markers of energy
generation and amplification of markers of oxidative stress
and inflammation [4]. These alterations are inferred to
correlate with fatigue, a patient-centered outcome not re-
ported in the several prior SLE fish oil supplementation
studies. Fatigue impacts 86 % of SLE patients and incon-
sistently correlates with disease activity [15, 16]. Of rele-
vance, supplementation with omega-3 fatty acids has been
associated with improvement in quality of life and depres-
sive symptoms in elderly depression [17]. The possibility
that the fatty acid profile impacts fatigue through meta-
bolic processes in SLE prompted a randomized placebo-
controlled trial of fish oil in SLE.
Methods
Patients and setting
Recruitment for this randomized, single-blind placebo
controlled clinical trial occurred in outpatient rheumatol-
ogy and nephrology clinics in a large urban hospital in
Dallas, Texas. Patients were 18–64 years old and had SLE
according to the 1997 revised ACR criteria [18]. Key ex-
clusion criteria were allergy to fish or fish oil, current use
or use within 2 months of fish oil supplements, warfarin
or heparin use, and pregnancy. The Institutional Review
Board approved the study protocol and all patients pro-
vided written informed consent prior to the study (Clini-
calTrials.gov Identifier NCT02021513). A total of 50
patients were randomized, 25 to fish oil and 25 to olive
oil placebo. The patients continued receiving medical
care from their primary care physicians and specialists
who were blinded to treatment group during the trial.
Study design
A 6 month single center, randomized, single-blind (patient
unaware of treatment group), placebo-controlled, parallel-
group pilot study of fish oil in SLE was conducted. Patients
were randomized using a simple block randomization 1:1
to receive fish oil (6 capsules/day equaling 2.25 g EPA and
2.25 g DHA Metagenics, Inc. Gig Harbor, WA) or visually
identical placebo (6 capsules/day purified [refined, not
extra-virgin] olive oil Metagenics) in addition to their
background therapies, with treatment duration of
6 months. The dose chosen was approximately equivalent
to the total EPA and DHA dose used in a prior lupus
nephritis study [12], as well as multiple other kidney dis-
eases as outlined in a meta-analysis [19]. All fish oil cap-
sules were encapsulated in the same lot under the
Norwegian Medicines Agency (Norway’s equivalent of the
Food and Drug Administration) with external testing to
verify EPA and DHA levels as well as impurity assessment
for safety. Patients were allowed to divide their treatment
into one or two doses per day, a daily total of 6 capsules.
Basic demographic and clinical information was collected
at baseline including: gender, race, ethnicity, age, body
mass index (BMI), duration of SLE, number of ACR cri-
teria, hypertension, diabetes, and tobacco use. Global diet-
ary routine was also evaluated using Rate Your Plate
(RYP), a dietary recall assessment tool. On this scale, 27–
45 indicates poor diet, 46–63 is average with ability to im-
prove eating habits, and 64–81 indicates a healthy diet
[20]. Use of the following medications was assessed at
baseline and study completion: prednisone, hydroxychlor-
oquine, mycophenolate mofetil, azathioprine, cyclophos-
phamide, statin (HMG-CoA reductase inhibitor), and
Angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker (ACEI or ARB).
Efficacy assessments
Disease activity was assessed at baseline and at 6 months
using the Safety of Estrogens in Lupus Erythematosus
National Assessment – Systemic Lupus Erythematosus
Disease Activity Index (SELENA-SLEDAI) score and
Physician Global Assessment (PGA) visual analogue
scale [21–23]. For both disease activity measures, higher
scores indicate worse disease activity with negative
change from baseline (6 months – baseline) indicating
improvement. The renal parameters of the SELENA-
SLEDAI were assessed in the 24 completer patients with
lupus nephritis to determine if additional benefits were
apparent in this subgroup. Quality of life was assessed
with the RAND 36-Item Health Survey Version 1.0
(RAND SF-36) that results in 8 subscales: Physical func-
tioning, Role functioning/physical, Role functioning/
emotional, Energy/fatigue, Emotional well-being, Social
functioning, Pain, and General health [24]. Higher scores
indicate a better quality of life and therefore a positive
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change from baseline denotes improvement. In addition
to the Energy/fatigue subscale of the RAND SF-36,
fatigue was assessed with the Fatigue Severity Scale
(FSS) with lower scores indicating less fatigue and nega-
tive change from baseline denoting improvement [25].
Both scales have been utilized in prior evaluations of
SLE patients [26]. The scores were all assessed by the
same evaluator (unblinded) for consistency.
Biomarker assessments
Baseline and 6 month serum soluble mediator panels
were assessed (EGF, eotaxin, FGF-basic, G-CSF, GM-
CSF, HGF, IFN-alpha, IFN-gamma, IL-10, IL-12, IL-13,
IL-15, IL-17, IL-1beta, IL- 1RA, IL-2, IL-2R, IL-4, IL-5,
IL-6, IL-7, IL-8, IP-10/CXCL10, MCP-1/CCL2, MIG/
CXCL9, MIP-1alpha/CCL3, MIP-1beta/CCL4, RANTES/
CCL5, TNFalpha, and VEGF) using the Luminex mag-
netic 30-plex human cytokine panel (Luminex ®, Austin,
TX). Additionally, serum malondialdehyde (MDA) was
assessed using the Thiobarbituric Acid Reactive Sub-
stances (TBARS) assay (Cayman Chemical Company,
Ann Arbor, MI). Available clinical laboratory data were
also evaluated including double-stranded DNA antibody
(Anti-dsDNA), complement 3 (C3), complement 4 (C4),
creatinine, ESR, C - reactive protein (CRP), lipid panel,
and spot urine protein to creatinine ratio.
Statistical analysis plan
SPSS V21 was used to analyze these data. Sample size
was determined using previously reported fish oil studies
carried out using different dosage, patient populations,
and assessments [8, 9, 11–14, 17]. Based on a target
sample size of 20 patients in each group at completion
and assuming a 20 % drop out rate, 25 patients were
randomized to each arm of the trial. Modified intention-
to-treat analyses were performed and included all patients
with more than baseline data. Categorical measures were
compared using Chi-square or Fisher’s Exact test, as ap-
propriate, and continuous measures using either a t-test,
Mann–Whitney, ANOVA, or Kruskal-Wallis, as appropri-
ate. Difference scores were calculated for all continuous
measures subtracting baseline measures from 6 month
measures (end of study-baseline).
Results
Patient population
One hundred and twelve patients presenting with a diag-
nosis code for SLE were assessed for eligibility and their
progression through the phases of the study is detailed
in the flow diagram (Fig. 1). Nineteen were excluded for
the following reasons: currently taking fish oil (n = 4),
allergy to fish oil (n = 1), anticoagulation (n = 3), met less
than 4 ACR criteria for SLE (n = 5), overlap syndrome
(n = 4), and other (n = 2). Ninety-three patients were
approached for consent and 43 refused. Fifty patients
were recruited and randomized 1:1 to fish oil treat-
ment or olive oil placebo. Randomization resulted in
two groups with similar demographics with the exception
of higher age, BMI, and hypertension comorbidity in the
fish oil group compared to the placebo group (Table 1).
Overall, patients were 84 % female, with a median age of
38.79 (range: 19.80–57.65), 44 % Hispanic/Latino, 54 %
Black/African American, 2 % White. Median BMI was
29.3 (range: 17.2–49.7), at the high end of being over-
weight. At baseline the median RYP score was 56.5 (range:
39–75), corresponding with average diet and ability to im-
prove eating habits, with no significant difference between
groups. Background medications at baseline and comple-
tion did not significantly differ between groups.
At study completion, 18 patients remained in the fish
oil group and 14 in the placebo group. Six of the 18
dropouts were lost to follow-up, 3 in each arm repre-
senting 12 % of the initial study sample. These patients
either self-reported by telephone or an immediate family
member confirmed they had continued taking the study
medication without side-effects, but for various reasons
failed to attend their study completion appointment.
Additional reasons for dropout included requirement to
take what was considered too many pills by patients in-
cluding 2 in the fish oil group and 3 in the placebo
group (p > 0.99). Side-effects that were cited as the cause
for dropout were all gastrointestinal (2 fish oil and 5 pla-
cebo p = 0.42) and not significant (burping, 1 in each
arm p > 0.99; nausea, 3 in the placebo group, p = 0.23;
diarrhea, 1 in the fish oil group, p > 0.99; and abdominal
pain, 1 in the placebo group, p > 0.99). Additionally, two
completers reported the side-effect of burping (1 in each
arm). Completers reported the ease of treatment as be-
ing very difficult (n = 2, 6 %), somewhat difficult (n = 15,
47 %), neutral (n = 9, 28 %), somewhat easy (n = 3, 9 %),
and easy (n = 3, 9 %), with no significant difference re-
lated to the treatment group (p = 0.897). All completers
consumed greater than 50 % of their treatment. Fifteen
of eighteen (83 %) fish oil subjects and nine of fourteen
(64 %) placebo subjects consumed greater than 75 % of
their treatment. When completers were asked if they
thought they would purchase over-the-counter fish oil
supplements and begin taking them regularly, 26 out of
32 (81 %) responded in the affirmative. To examine if
the patients were blinded to treatment allocation, com-
pleters were asked if they believed they knew their treat-
ment group. Eleven patients stated that they did not
believe they knew whether they had received fish oil or
olive oil placebo (6 fish oil and 5 placebo). Twelve
(67 %) of fish oil and 9 (64 %) of placebo patients
believed they were taking fish oil (p > 0.99). No patients
believed they were receiving placebo. Medications at
baseline and completion are shown in Table 2. The
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unblinded evaluator did not alter medications for the
duration of the study. For accuracy, change in pred-
nisone dose was analyzed as a continuous variable to
determine if significant changes in dose occurred be-
tween groups, with no significant difference being
found (p = 0.929). Hydroxychloroquine use was sur-
prisingly near complete in the patients. Other im-
munosuppressant use did not vary significantly between
groups. Statin use was similar at baseline between groups
(p = 0.235), but significantly higher in the fish oil patients
at completion (p = 0.0276). McNemar’s test did not note a
significant difference between baseline and completion of
statin use for the fish oil group (p = 0.248) or the placebo
group (p > 0.999).
Efficacy of fish oil quality of life/fatigue
Comparison of score changes for the Energy/fatigue sub-
scale of the Rand SF-36 utilizing the Mann–Whitney test
yielded a trend in improvement for the fish oil group
(median 10.00 [IQR - 1.25 – 21.25]) compared to the
placebo group (−2.50 [−6.25 – 11.25], p = 0.092; Fig. 2a).
Another related subscale, Emotional well-being also
demonstrated a trend in improvement in the fish oil
group (16.00 [−1.00 – 33.00] compared to the placebo
group (4.00 [−5.00 – 14.00], p = 0.070; Fig. 2b). The FSS
change scores were quite similar between the fish oil
patients (− 0.056 [−1.500 – 0.500] and placebo patients
(0.222 [−0.556–0.667], p = 0.350; Fig. 2c).
Inexplicably, the fish oil group reported lower scores
at baseline for the RAND SF-36 and higher scores on
the FSS, indicating worse quality of life and worse
fatigue (Table 3). The radial diagrams representing all 8
subscales of the RAND SF-36 allow better visualization
of the baseline differences as well as areas with greater
improvement (Fig. 3).
Disease activity
In addition to evaluating fatigue, we assessed disease activ-
ity using the PGA and SELENA-SLEDAI. The fish oil
patients exhibited improvement in global disease activity
(−0.550 [−1.275– - 0.100] compared to the placebo pa-
tients (0.50 [−0.200–0.350]) based on the PGA (p = 0.015;
Fig. 4a). The change in SELENA-SLEDAI (fish oil −1.00
[−4.5–4.25] and placebo 0.00 [− 0.50–2.00]) and the
change in renal SELENA-SLEDAI (24 lupus nephritis pa-
tients only; fish oil 0.00 [−4.00–1.00] and placebo 0.00
[0.00–0.00]) scores did not indicate a significant difference
between the two groups (p = 0.417 and p = 0.350, respect-
ively; Fig. 4b and c). Baseline comparison of disease
Approached for Consent (N=93)
Randomized (N=50)
Analyzed (N=14) Analyzed (N=18)
Quit Taking (N=4)
Too Many Pills (N=2)
Burping (N=1)
Diarrhea (N=1)
Lost To Follow-up – available by 
telephone but unable to aend 
clinic appointment (N=3)
Quit Taking (N=8)
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Allocated to Placebo (N=25) Allocated to Fish Oil (N=25)
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Fig. 1 Trial Profile. Flow diagram of progress through phases of the randomized clinical trial
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activity measures in the trial completers did not indicate
significant difference between the groups.
Changes in bomarkers
Additional laboratory tests were evaluated for changes
during treatment. ESR, an accepted measure of sys-
temic inflammation, demonstrated a significant reduc-
tion in the fish oil group compared to the placebo
group (fish oil −5.0 [−39.0– -2.5] and placebo 4.5 [0.0–
19.0], p = 0.008; Fig. 5a). Among the cytokines/chemo-
kines/growth factors studied, we observed an increase
in the level of IL-13 (fish oil −3.89 [−17.37–38.55] and pla-
cebo −16.86 [−46.25–2.31], p = 0.033; Fig. 5b) and a de-
crease in the level of IL-12 (fish oil −16.13 [−78.50–26.37]
and placebo 8.54 [−14.16–113.35], p = 0.058); Fig. 5c).
Discussion
Fatigue and reduced quality of life commonly impact
SLE patients. Metabolomic profiling in SLE alluded to a
reduction in markers of energy generation as well as in-
creased markers of inflammation [4]. These alterations
may manifest physically and mentally as ill-defined
Table 1 Baseline demographic and clinical features of the placebo and treatment groups
All Completers
Placebo (N=25) Fish oil (N=25) Placebo (N=14) Fish oil (N=18)
Demographics
Sex, female 22 (88 %) 20 (80 %) 11 (79 %) 14 (78 %)
Age, years 36.1 [28.6–41.0]a 46.1 [34.7–49.3]a 35.6 [26.3–42.7]a 46.2 [36.8–49.1]a
Ethnicity
Hispanic/Latino 11 (44 %) 11 (44 %) 7 (50 %) 8 (44 %)
Black/African American 13 (52 %) 14 (56 %) 6 (43 %) 10 (56 %)
White 1 (4 %) 0 (0 %) 1 (7 %) 0 (0 %)
BMI 25.0 [23.4–32.6]a 31.4 [27.5–40.2]a 26.0 [23.7–33.0]a 35.4 [29.0–42.0]a
Rate Your Plate 55 [50–60] 57 [52–63] 56 [50–61] 58 [53–64]
Comorbidities
HTN 13 (52 %)a 20 (8O%)a 6 (43 %)a 15 (83 %)a
DM2 1 (4 %) 6 (24 %) 1 (7 %) 4 (22 %)
Tobacco Use 5 (20 %) 7 (28 %) 5 (36 %) 6 (33)%
Disease Characteristics
SELENA-SLEDAI 8 [2–10] 6 [3–10.5] 4 [0–3.5] 7 [3.5–11.25]
Disease duration, years 6 [2–10] 6 [3–11] 5.5 [l.8–9.3] 6 [2.8–10.5]
ACR Criteria, total number 6 [5–7] 5 [5–7] 5 [4–7] 5.5 [5–7]
Lupus Nephritis 18 (72 %) 17 (68 %) 10 (71 %) 14 (78 %)
Medication
Prednisone
0 mg/day 7 (28 %) 11 (44 %) 5 (36 %) 7 (39 %)
≤7.5 mg/day 8 (32 %) 4 (16 %) 5 (36 %) 2 (11 %)
>7.5 mg/day 10 (40 %) 10 (40 %) 4 (29 %) 9 (50 %)
Hydroxychloroquine 22 (88 %) 22 (88 %) 12 (86 %) 16 (89 %)
Other Immunosuppressants
Cyclophosphamide 0 (0 %) 2 (8 %) 0 (0 %) 1 (6 %)
Mycophenolate 11 (44 %) 11 (44 %) 8 (57 %) 7 (39 %)
Azathioprine 4 (16 %) 1 (4 %) 2 (14 %) 0 (0 %)
Misc. Medications
Statin 5 (20 %) 8 (32 %) 2 (14 %) 7 (39 %)
ACEI/ARB 16 (64 %) 15 (60 %) 9 (64 %) 12 (67 %)
Characteristics of the fish oil treatment group and olive oil placebo group, for both the intial randomized patient groups (N=50) and the completers (N=32). Data
presented as number of patients (%) or median and interquartile range [IQ.R]. Statistically significant differences (p<0.05) comparing fish oil and placebo groups
are indicated with a superscript a(a)
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symptoms of fatigue, generalized pain, and depressed
mood. Also noted in the metabolomic study was a re-
duction in serum omega-3 fatty acids [4].
Supplementation with omega-3 fatty acids through fish
oil has resulted in improvement in quality of life in dis-
eases other than lupus. This trial is the first to investi-
gate the impact of fish oil supplementation on fatigue
and quality of life in patients with SLE. We have also
evaluated disease activity and a variety of serum bio-
markers. We found that fish oil supplementation
resulted in improvement in quality of life, disease activ-
ity, and biomarkers of inflammation.
The Fatigue Severity Scale did not appear to be a
metric capable of capturing subtle changes in a small
group of patients, as majority of scores remained approxi-
mately the same at both time points. However, the RAND
SF-36 did indicate positive improvement trends for the
Energy/fatigue and Emotional well-being subscales. Due
to the large difference in baseline values the results are
somewhat difficult to interpret. Attempt to incorporate
baseline values as a covariate resulted in loss of improve-
ment signals in this small group of patients. Our results
are consistent with fish oil studies in other disorders. A
meta-analysis found fish oil to have a positive effect on
major depressive disorder, using various validated depres-
sion metrics [27]. Included in that meta-analysis is a study
of elderly depressed women that included SF-36 evalu-
ation, where they noted improvement in the mental health
Table 2 Medications at baseline and six months
Placebo (N=14) Fish oil (N=18)
Baseline Six months Baseline Six months
Prednisone
0 mg/day 5 (36 %) 7 (50 %) 7 (39 %) 5 (28 %)
≤7.5 mg/day 5 (36 %) 4 (29 %) 2 (11 %) 1 (6 %)
>7.5 mg/day 4 (29 %) 3 (21 %) 9 (50 %) 12 (67 %)
Median [IQR] mg/day 5 [0–20] 3 [0–9] 8 [0–20] 10 [0–15]
Hydroxychloroquine 12 (86 %) 14 (100 %) 16 (89 %) 16 (89 %)
Other Immunosuppressants
Cyclophosphamide 0 (0 %) 1 (7 %) 1 (5 %) 1 (5 %)
Mycophenolate 8 (57 %) 7 (50 %) 7 (39 %) 10 (56 %)
Azathioprine 2 (14 %) 2 (14 %) 0 (0 %) 0 (0 %)
Misc. Medications
Statin 2 (14 %) 2 (14 %) 7 (39 %) 10 (56 %)
ACE/ARB 9 (64 %) 9 (64 %) 12 (67 %) 14 (78 %)
Background medications for all completers at baseline and study completion. Data presented as number of patients (%) or median and interquartile range [IQR]
 
p=0.092 p=0.070 p=0.350 
A B C 
Fig. 2 Quality of Life Assessments. RAND Short Form-36 (SF-36) Dot plot of score changes from baseline to six months for a Energy/fatigue
(p = 0.092) and b Emotional Well- Being (p = 0.070), a higher score is indicative of better quality of life or fatigue; therefore a positive delta
denotes improvement. Fatigue Severity Scale c Dot plot of score changes from baseline to six months (p = 0.350), a lower score indicates less
fatigue; therefore a negative delta denotes improvement. For all graphs, center bar represents median and upper and lower bars are the 25th
and 75th percentiles. Data were analyzed with Mann–Whitney U tests
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(equivalent to Emotional well-being) subscale, though no
clear difference was seen in the vitality (Energy/fatigue)
subscale [17]. Fish oil supplementation improved quality
of life in patients with dry eyes [28]. Evaluation of 3 clin-
ical trials in multiple sclerosis concluded fish oil to be in-
effective for fatigue and quality of life [29]. Our results
suggest that fish oil may be beneficial for particular as-
pects of health related quality of life and further studies in
this area are warranted.
Disease activity was assessed using the SELENA-
SLEDAI and PGA. There was not a clear difference in
SELENA-SLEDAI between the groups. However, the PGA
indicated a positive signal with fish oil therapy. Perhaps
the PGA integrated aspects of mental health and quality
of life not captured by the SLEDAI as well as contextualiz-
ing aspects of disease activity that may be more or less
relevant in a particular patient. Fish oil has been noted to
have variable effects on disease activity in previous studies
[7, 8, 11–14]. The amount and duration of the fish oil used
varied widely in those prior studies. In a meta-analysis of
several chronic renal diseases including IgA nephropathy,
diabetic nephropathy, and one study of lupus nephritis,
fish oil was found to have the beneficial effect of reducing
proteinuria, but not improving GFR [19]. Reduced pro-
teinuria, improved GFR, and improved survival were
treatment effects of fish oil in murine lupus nephritis
models [30–33]. The majority of our patients had lupus
nephritis (LN). Hence this subset was evaluated for renal-
specific parameters of the SLEDAI as well as their spot
protein to creatinine ratios, though fish oil did not appear
to strongly impact either. A previous clinical trial found
similar results [12].
Multiple biomarkers were assessed including markers of
inflammation, cytokines, chemokines, and growth factors.
Table 3 RAND SF-36 at baseline, six months, and baseline-six months
Placebo (N=14) Fish oil (N=18} Mann–Witney U
Median [IQR] Median [IQR] p-value
Baseline
Physical functioning 75.00 [52.90–90.00] 32.5 [17.50–55.00] .004
Role functioning/physical 75.00 [0.00–100.00] 0.00 [0.00–25.00] .022
Role functioning/emotional 66.67 [0.00–100.00] 0.00 [0.00–16.67] .021
Energy/fatigue 55.00 [28.75–76.25] 20.00 [10.00–46.25] .016
Emotional well-being 68.00 [60.00–89.00] 40.00 [28.00–64.00] .006
Social functioning 68.75 [46.88–90.63] 37.50 [21.88–62.50] .006
Pain 62.50 [45.00–92.50] 22.50 [9.38–47.50] .001
General health 42.50 [28.75–62.50] 30 [18.75–50.00] .100
Six Months
Physical functioning 77.50 [48.75–96.25] 30.00 [15.00–51.25] .005
Role functioning/ physical 75.00 [43.75–100.00] 0.00 [0.00–75.00] .015
Role functioning/ emotional 100.00 [50.00–100.00] 16.67 [0.00–100.00] .217
Energy/fatigue 55.00 [32.50–70.00] 37.50 [20.00–56.25] .138
Emotional well-being 78.00 [61.00–88.00] 66.00 [44.00–77.00] .037
Social functioning 68.75 [50.00–100.00] 50.00 [25.00–75.00] .023
Pain 72.50 [46.25–92.50] 32.5 [22.50–57.50] .009
General health 52.50 [20.00–60.00] 37.50 [30.00–51.25] .380
Six Months-Baseline
Physical functioning 5.00 [-10.00–21.25] -2.50 [-10.00–16.25] .468
Role functioning/physical 0.00 [0.00–25.00] 0.00 [0.00–25.00] .878
Role functioning/emotional 0.00 [0.00–33.33] 0.00 [0.00–50.00] .693
Energy/fatigue -2.50 [-6.25–11.25] 10.00 [-1.25–21.25] .092
Emotional well-being 4.00 [-5.00–14.00] 16.00 [-1.00–33.00] .070
Social functioning 6.25 [-9.38–18.75] 6.25 [-12.50–37.50] .657
Pain -11.25 [-14.38–18.13] 10.00 [0.00–25.00] .105
General health -2.50 [-10.00–6.25] 5.00 [-11.25–23.75] .312
RAND SF-36 data are presented as median and interquartile range (IQR) for all completer patients at baseline, study completion, and difference between baseline
and six months
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ESR, assessed through standard of care laboratory testing,
was found to be significantly reduced in the fish oil group
as compared to the placebo. This finding is an indication
of a reduction in inflammation in these patients. Prior
studies did not report a change in ESR in SLE patients re-
ceiving fish oil compared to placebo [8, 11]. However, ESR
was found to be reduced in peritoneal dialysis patients
[34] and rheumatoid arthritis patients given fish oil [35].
The role of IL-13, a T-cell secreted anti-inflammatory
cytokine, in SLE and LN is quite complex as active LN
patients have elevated serum levels and increased kidney
tissue transcription of the IL13 gene [36]. We found that
treatment with fish oil increased the level of IL-13 as com-
pared to placebo. Cultured lymph node cells from a
mouse model of allergic airway disease also noted in-
creased IL-13 in cells derived from the fish oil fed mice
[37]. Fish oil supplementation also increased IL-13 in lung
tissue of a murine model of allergic inflammation [38]. It
is conceivable that the increased Th2 skewing induced by
the elevated IL- 13 may be beneficial in SLE. IL-12 is a
pro-inflammatory cytokine that is elevated in SLE [36].
We find fish oil supplementation reduces serum IL-12 in
SLE patients as compared to placebo. In a mouse model
of SLE, MRL/lpr, fish oil supplementation was found to
reduce IL-12 serum levels. Infectious challenge resulted in
reduced IL-12 level in fish oil fed healthy mice [39, 40].
Omega-3 fatty acids have been noted to have anti-
inflammatory properties including alteration to cytokine
signaling and anti-oxidant effects in a recent mechanistic
study [10]. Our findings of fish oil supplementation result-
ing in reduced ESR and IL-12, as well as increased IL-13
are in concordance with published human and animal
 
p=0.015 p=0.42 p=0.35 
A B C 
Fig. 4 Disease Activity Assessments. Physician’s Global Assessment a Dot plot of score changes (p = 0.015), a higher score is indicative of worse overall
disease activity; therefore a negative delta denotes improvement. SELENA-SLEDAI b Dot plot of change scores (p = 0.42) and c Renal component delta
for LN patients only, Placebo N = 10 and Fish Oil N = 14, (p = 0.35), a higher score is indicative of higher disease activity; therefore a negative delta de-
notes improvement. For all graphs, center bar represents median and upper and lower bars are the 25th and 75th percentiles. Data were analyzed with
Mann–Whitney U tests
Fig. 3 Quality of Life Assessments. RAND Short Form-36 (SF-36) Radial representation of the means of the 8 subscales as assessed at baseline
(solid line) and six months (dotted line). a Placebo completers (N = 14) & b Fish Oil completers (N = 18)
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studies. Importantly, these results add to the plausibility of
fish oil resulting in reduced inflammation through mul-
tiple molecular mechanisms, including alterations in Th1/
Th2 balance.
We recognize that our study had several limitations.
This study was underpowered for the fatigue and quality
of life outcomes. Additionally, although randomization
resulted in two similar groups based on demographics
with the exception of older age and higher BMI in the
fish oil group, the latter group had worse quality of life
and fatigue at baseline. Age and BMI may have contrib-
uted to the disparity in baseline quality of life measures.
Randomization is performed in order to match groups
on both measured variables as well as unmeasured vari-
ables. In large studies randomization results in well
matched groups, however in smaller studies random dif-
ferences in measured variables are still possible. The
major cause of dropout was failure to follow-up in clinic.
Studies with dropouts less than 20-30 % are acceptable
for performing unmodified intention-to-treat analysis
and imputation, however our study resulted in 36 %
dropouts [41, 42]. Although the patients were blinded to
treatment, the investigator was able to discern the treat-
ment groups. Besides physician global assessment and
selected components of the SLEDAI, all remaining mea-
sures were objective or patient-reported. A portion of
fish oil patients believed they were un-blinded to their
treatment group; however a similar number of placebo
patients incorrectly believed they were taking fish oil.
Multiple patients were undergoing therapy with immu-
nosuppressives and glucocorticoids, which was un-
avoidable as we desired the inclusion of patients with
active disease. Future trial design could benefit from a
placebo run-in period to minimize dropout, inclusion
of larger numbers of patients, stratification to ensure
balanced treatment groups, double-blinding, and un-
modified intention-to-treat analysis.
Conclusions
This study indicates fish oil has potential benefits in
SLE. Fish oil is a minimal risk, widely available oral
supplement. The strengths of this study were the inclu-
sion of a concurrent placebo arm, randomization of the
two groups, and patients being blinded to their treat-
ment. An additional strength is the novel assessment of
fish oil’s effect on quality of life, fatigue, and a large
panel of soluble mediators in SLE patients. Although
the study evaluated a small group of patients, there
were positive indications in the treatment group for
quality of life, fatigue, disease activity, and inflamma-
tion biomarkers. Further studies are warranted to
confirm our promising findings.
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